openPR Logo
Press release

Investigation for Investors in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

08-29-2019 04:16 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares over potential securities laws violations.

An investigation for investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares over potential securities laws violations.

An investigation was announced concerning potential securities laws violations by Sarepta Therapeutics, Inc. in connection with certain financial statements.

Investors who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Sarepta Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. On August 19, 2019, Sarepta Therapeutics, Inc. announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food & Drug Administration regarding the Company’s New Drug Application seeking accelerated approval of golodirsen injection for the treatment of Duchenne muscular dystrophy. Sarepta disclosed that “[t]he CRL generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides.” Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) declined to as low as $90.24 per share on August 22, 2019.

Those who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for Investors in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) here

News-ID: 1827979 • Views:

More Releases from Shareholders Foundation

Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to recover losses
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements. Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover losses
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc.. Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Malvern, PA based Ocugen, Inc., a
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) should contact the Shareholders Foundation in connection with Lawsuit
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV
Investigation announced for Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) over possible Violations of Securities Laws
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Sarepta

2022 Casimersen Market Report- Industry Analysis, Size, Share, Trends, Segmentat …
The Casimersen Market research report also provides factors impacting and changes in regulation in the market domestically that impact the current and future trends of the Casimersen Market. In addition, Casimersen Market insights like volume, production, sites, consumption, price trend analysis, cost of raw material, downstream and upstream value chain analysis are significant factors used to forecast the market scenario for developing countries. Get FREE PDF Sample of the Report @
Gene Therapy Market 2021 Precise Outlook - Biogen, Novartis, Gilead Sciences, Sa …
The "Gene Therapy" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global Gene Therapy Industry presents a market overview, product details, classification, and market concentration. The report also provides an in-depth survey of key players in the market which is based on various competitive intelligence parameters like company profiles, product picture and specification,
Global Oligonucleotide API Market Huge B2B opportunities 2021_26 | Jazz Pharmace …
(United States, OR Poland): Global Oligonucleotide API Market 2021-2026 analysis report gives a comprehensive competitive evaluation that covers designated company profiling of leading players in Oligonucleotide API Market size report, a take a look at on the nature and characteristics of the competitive landscape, and other crucial studies. New players also can use this Oligonucleotide API record to create enterprise strategies and get knowledgeable about Oligonucleotide API future market challenges.
Investigation announced for Investors in shares of Sarepta Therapeutics, Inc. (N …
An investigation was announced over potential securities laws violations by Sarepta Therapeutics, Inc. in connection with certain financial statements. Investors who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Sarepta Therapeutics, Inc. regarding its business, its prospects and its operations were
Global Oligonucleotide-based Therapies Market 2020 Business Strategies - Biogen, …
The market exploration report titled Global Oligonucleotide-based Therapies Market Growth (Status and Outlook) 2020-2025 provides an investigation of the most recent market patterns like market development openings, size, share, and drivers. The report looks at the market status and future trends. The report focuses on the market size, market share, market positioning, product type, and important roles of the players in the global Oligonucleotide-based Therapies market. It explains the market’s
Investigation for NASDAQ: SRPT Investors over potential Wrongdoing at Sarepta Th …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Sarepta Therapeutics, Inc.. Investors who are current long term investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: SRPT stocks follows a lawsuit filed against Sarepta Therapeutics, Inc.